Financial commitment expected to expand the development and commercialization pipeline for new medicines
AstraZeneca will be establishing an active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure that the company’s global supply network is ready for growth.
The new plant will offer late-stage development and early commercial supply, with the help of state-of-the-art process technology.
The $360 million planned investment at the Alexion Campus in College Park, Dublin, is anticipated to add about 100 highly skilled direct jobs, featuring scientists and engineers, among others. Company officials expect the project, which was created with the support and collaboration of Ireland’s investment agency, IDA Ireland, to provide the opportunity to manufacture various types of medicines, including new modalities, such as antibody drug conjugates and oligonucleotides.
“The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis, requiring next generation technologies and capabilities that can respond quickly and nimbly to rapidly-changing clinical and commercial needs,” says Pam Cheng, executive vice president of global operations and IT. “This significant investment will ensure the AstraZeneca supply network is fit for the future.”